Can Trisol’s TTVR platform solve the right heart puzzle in tricuspid regurgitation care?
Trisol’s valve shows early safety and efficacy in high-risk TR patients. Explore what this means for the future of transcatheter tricuspid therapies.
Will the TricValve pivotal trial finally solve the unmet needs in severe tricuspid regurgitation?
P&F Products and Features GmbH, the Austria-based cardiovascular device innovator, has secured approval from the U.S. Food and Drug Administration to initiate the TRICAV II pivotal clinical trial. The study will evaluate the TricValve Transcatheter Bicaval Valve System for severe tricuspid regurgitation, aiming to provide a minimally invasive option for patients who currently have no […]